These are top 10 stocks traded on the Robinhood UK platform in July
Morgan Stanley (NYSE:MS) initiated coverage on Hinge Health Inc (NYSE:HNGE) Monday with an overweight rating and a $46.00 price target, representing significant upside from the current price of $34.85. InvestingPro data shows the company maintains strong financial health with an impressive 79.46% gross profit margin and a healthy current ratio of 2.31.
The investment bank identified Hinge Health as the leading virtual platform providing physical therapy for musculoskeletal (MSK) issues, which represents a $27 billion serviceable available market. MSK issues rank among the top three cost concerns for most large employers.
Unlike many digital health companies that experienced growth slowdowns after pandemic-era surges, Hinge Health has demonstrated accelerating year-over-year growth, reaching 44% and 50% in the two most recent quarters.
Morgan Stanley cited several factors supporting its positive outlook, including Hinge Health’s strong product return on investment (2.4:1), strategic channel partnerships with leading health plans and pharmacy benefit managers, and positive user feedback.
The company’s performance contrasts with the broader digital health sector, where many firms have seen growth rates decline to single digits following the COVID-19 spending boom.
In other recent news, Hinge Health Inc has garnered attention from several investment firms with positive assessments of its market position and growth potential. RBC Capital Markets initiated coverage with an outperform rating and a $45 price target, emphasizing the company’s leadership in digital musculoskeletal care and its potential for margin expansion. KeyBanc Capital Markets also initiated coverage, assigning an overweight rating and the same $45 price target, noting Hinge Health’s strong position in the underserved musculoskeletal market and its proprietary technology.
KeyBanc highlighted the company’s shift to a utilization-based pricing model and ongoing product expansions as catalysts for growth. Stifel joined the positive outlook by initiating a buy rating with a $48 price target, citing Hinge Health’s virtual physical therapy platform and its ability to reduce healthcare costs for employers and health plans. Stifel noted the company’s expansion into fully-insured plans like Medicare Advantage as a significant growth opportunity.
All three firms recognized Hinge Health’s competitive advantages, such as its technology, integration capabilities, and established distribution channels. These developments reflect the company’s strategic positioning in a growing market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.